Literature DB >> 1657936

Isoform-specific transforming growth factor-beta binding proteins with membrane attachments sensitive to phosphatidylinositol-specific phospholipase C.

S Cheifetz1, J Massagué.   

Abstract

We report the identification of cell surface glycoproteins that bind transforming growth factor-beta (TGF-beta) in an isoform-specific manner, and are distinct from TGF-beta receptors I and II or the TGF-beta binding proteoglycan beta-glycan. The novel TGF-beta binding proteins have been identified in various cell lines including fetal bovine heart endothelial cells and MG-63 human osteosarcoma cells. They include proteins of 90-100 and 180 kDa that preferentially bind TGF-beta 1 (KD 0.1-0.2 nM) and proteins of 60 and 140 kDa that preferentially bind TGF-beta 2 (KD 0.5-1 nM). The 180-kDa TGF-beta 1 binding protein and the 60- and 140-kDa TGF-beta 2 binding proteins can be released from the cell surface by treatment with phosphatidylinositol-specific phospholipase C, suggesting that these proteins are attached to the plasma membrane through a phosphatidylinositol anchor. The expression of these three proteins as well as their sensitivity to phosphatidylinositol-specific phospholipase C is cell line-dependent. The 90-100-kDa TGF-beta 1 binding proteins are components of a 190-kDa disulfide-linked complex. The structural properties of these proteins and their high affinity and selectivity for different TGF-beta isoforms defines them as a novel class of cell surface TGF-beta binding proteins.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657936

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Identification of a structural domain that distinguishes the actions of the type 1 and 2 isoforms of transforming growth factor beta on endothelial cells.

Authors:  S W Qian; J K Burmester; J R Merwin; J A Madri; M B Sporn; A B Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

2.  Type III TGF-beta receptor-independent signalling of TGF-beta2 via TbetaRII-B, an alternatively spliced TGF-beta type II receptor.

Authors:  D Rotzer; M Roth; M Lutz; D Lindemann; W Sebald; P Knaus
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

3.  Transforming growth factor beta 1 gene expression in human airways.

Authors:  J D Aubert; B I Dalal; T R Bai; C R Roberts; S Hayashi; J C Hogg
Journal:  Thorax       Date:  1994-03       Impact factor: 9.139

4.  Characterization of transforming growth factor-beta (TGF-beta) receptors on BeWo choriocarcinoma cells including the identification of a novel 38-kDa TGF-beta binding glycoprotein.

Authors:  E J Mitchell; K Lee; M D O'Connor-McCourt
Journal:  Mol Biol Cell       Date:  1992-11       Impact factor: 4.138

5.  Characterization of distinct functional domains of transforming growth factor beta.

Authors:  J K Burmester; S W Qian; A B Roberts; A Huang; S Amatayakul-Chantler; L Suardet; N Odartchenko; J A Madri; M B Sporn
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

6.  Oligomeric structure of type I and type II transforming growth factor beta receptors: homodimers form in the ER and persist at the plasma membrane.

Authors:  L Gilboa; R G Wells; H F Lodish; Y I Henis
Journal:  J Cell Biol       Date:  1998-02-23       Impact factor: 10.539

7.  Relationship between Axial Length and Levels of TGF-β in the Aqueous Humor and Plasma of Myopic Patients.

Authors:  Yuwen Hsiao; Yiting Cao; Yu Yue; Jibo Zhou
Journal:  Biomed Res Int       Date:  2021-02-26       Impact factor: 3.411

8.  Quantitative trait analysis reveals transforming growth factor-beta2 as a positive regulator of early hematopoietic progenitor and stem cell function.

Authors:  Jessica C Langer; Els Henckaerts; Jonathan Orenstein; Hans-Willem Snoeck
Journal:  J Exp Med       Date:  2004-01-05       Impact factor: 14.307

Review 9.  The Controversial Role of TGF-β in Neovascular Age-Related Macular Degeneration Pathogenesis.

Authors:  Gian Marco Tosi; Maurizio Orlandini; Federico Galvagni
Journal:  Int J Mol Sci       Date:  2018-10-27       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.